Literature DB >> 33590330

Trajectories of change in symptom severity in patients with fibromyalgia: exploratory analyses of a randomised controlled trial.

Trond Haugmark1,2, Kåre Birger Hagen3,4, Sella Aarrestad Provan3, Joseph Sexton5, Heidi A Zangi3,6.   

Abstract

The clinical picture of fibromyalgia (FM) symptoms fluctuates, and the symptom severity varies within and between patients. The current study aimed to identify groups of PDS trajectories and to explore differences in baseline characteristics between the potential groups of trajectories. We included patients from a completed randomised controlled trial, in total 170 patients diagnosed with FM according to the ACR 2010 criteria. The mean age was 40 years, and 94% were women. Symptom severity was assessed by the Polysymptomatic distress scale (PDS) [range 0 (no symptoms) to 31] at four timepoints over 13-18 months. Latent class growth analysis was used to identify patient trajectories based on their response pattern on the PDS. Potential differences in baseline characteristics between the trajectories were compared using appropriate statistical tests. Two distinct PDS trajectories were identified with 110 patients (65%) classified as the "no improvement" group and 60 (35%) as the "some improvement" group. Mean PDS scores at pre-baseline were ≥ 20 in both groups. At 12 months, the groups diverged, mean (SD) PDS score was 14 (3.82) in the "some improvement" group and 21 (4.12) in the "no improvement" group. There were no significant differences in baseline characteristics between the groups of PDS trajectories. We identified one group of FM patients that improved slightly during the study period and one group that not improved. There were no differences in baseline characteristics between the two groups.

Entities:  

Keywords:  Fibromyalgia; Latent class growth analysis; Polysymptomatic distress scale; Trajectory

Year:  2021        PMID: 33590330     DOI: 10.1007/s00296-021-04801-x

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  10 in total

1.  Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia.

Authors:  Frederick Wolfe; Daniel J Clauw; Mary-Ann Fitzcharles; Don L Goldenberg; Winfried Häuser; Robert S Katz; Philip Mease; Anthony S Russell; I Jon Russell; John B Winfield
Journal:  J Rheumatol       Date:  2011-02-01       Impact factor: 4.666

2.  Fibromyalgia 2016 criteria and assessments: comprehensive validation in a Norwegian population.

Authors:  Egil A Fors; Knut-Arne Wensaas; Hilde Eide; Ellen A Jaatun; Daniel J Clauw; Fred Wolfe; Anne-Sofie Helvik
Journal:  Scand J Pain       Date:  2020-10-25

3.  The changing states of fibromyalgia in patients with axial spondyloarthritis: results from BSRBR-AS.

Authors:  Sella A Provan; Linda E Dean; Gareth T Jones; Gary J Macfarlane
Journal:  Rheumatology (Oxford)       Date:  2021-01-06       Impact factor: 7.580

4.  The longitudinal outcome of fibromyalgia: a study of 1555 patients.

Authors:  Brian Walitt; Mary-Ann Fitzcharles; Afton L Hassett; Robert S Katz; Winfried Häuser; Frederick Wolfe
Journal:  J Rheumatol       Date:  2011-07-15       Impact factor: 4.666

5.  The Use of Polysymptomatic Distress Categories in the Evaluation of Fibromyalgia (FM) and FM Severity.

Authors:  Frederick Wolfe; Brian T Walitt; Johannes J Rasker; Robert S Katz; Winfried Häuser
Journal:  J Rheumatol       Date:  2015-06-15       Impact factor: 4.666

Review 6.  Predictors of multidisciplinary treatment outcome in fibromyalgia:a systematic review.

Authors:  Aleid de Rooij; Leo D Roorda; René H J Otten; Marike van der Leeden; Joost Dekker; Martijn P M Steultjens
Journal:  Disabil Rehabil       Date:  2012-08-14       Impact factor: 3.033

Review 7.  Fibromyalgia: a clinical review.

Authors:  Daniel J Clauw
Journal:  JAMA       Date:  2014-04-16       Impact factor: 56.272

8.  Fibromyalgia Outcomes Over Time: Results from a Prospective Observational Study in the United States.

Authors:  Caroline P Schaefer; Edgar H Adams; Margarita Udall; Elizabeth T Masters; Rachael M Mann; Shoshana R Daniel; Heather J McElroy; Joseph C Cappelleri; Andrew G Clair; Markay Hopps; Roland Staud; Philip Mease; Stuart L Silverman
Journal:  Open Rheumatol J       Date:  2016-11-30

9.  The Problematic Nature of Fibromyalgia Diagnosis in the Community.

Authors:  Sachin Srinivasan; Eamon Maloney; Brynn Wright; Michael Kennedy; K James Kallail; Johannes J Rasker; Winfried Häuser; Frederick Wolfe
Journal:  ACR Open Rheumatol       Date:  2019-03-15

10.  Effects of a community-based multicomponent rehabilitation programme for patients with fibromyalgia: protocol for a randomised controlled trial.

Authors:  Trond Haugmark; Kåre Birger Hagen; Sella Aarrestad Provan; Elisebeth Bærheim; Heidi A Zangi
Journal:  BMJ Open       Date:  2018-06-04       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.